SG11201906552WA - TGF-ß DECOY RECEPTOR - Google Patents
TGF-ß DECOY RECEPTORInfo
- Publication number
- SG11201906552WA SG11201906552WA SG11201906552WA SG11201906552WA SG11201906552WA SG 11201906552W A SG11201906552W A SG 11201906552WA SG 11201906552W A SG11201906552W A SG 11201906552WA SG 11201906552W A SG11201906552W A SG 11201906552WA SG 11201906552W A SG11201906552W A SG 11201906552WA
- Authority
- SG
- Singapore
- Prior art keywords
- tgf
- tower
- international
- temasek
- suntec
- Prior art date
Links
- 108700015048 receptor decoy activity proteins Proteins 0.000 title abstract 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450468P | 2017-01-25 | 2017-01-25 | |
| PCT/EP2018/051287 WO2018138003A1 (en) | 2017-01-25 | 2018-01-19 | TGF-ß DECOY RECEPTOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906552WA true SG11201906552WA (en) | 2019-08-27 |
Family
ID=61223877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906552WA SG11201906552WA (en) | 2017-01-25 | 2018-01-19 | TGF-ß DECOY RECEPTOR |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190352373A1 (zh) |
| EP (1) | EP3574006A1 (zh) |
| JP (1) | JP2020505069A (zh) |
| KR (1) | KR20190111058A (zh) |
| CN (1) | CN110709416A (zh) |
| AU (1) | AU2018212403A1 (zh) |
| SG (1) | SG11201906552WA (zh) |
| TW (1) | TW201831193A (zh) |
| WO (1) | WO2018138003A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249779A (zh) | 2019-11-12 | 2023-06-09 | 阿克蒂姆治疗有限公司 | 免疫刺激细菌递送平台及其用于递送治疗产物的用途 |
| CN115427451A (zh) * | 2020-02-14 | 2022-12-02 | 北京永泰瑞科生物科技有限公司 | 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途 |
| CA3183325A1 (en) * | 2020-05-19 | 2021-11-25 | The Regents Of The University Of California | Conjugate polypeptides and vaccines for inducing immune responses |
| CN111748043B (zh) * | 2020-07-03 | 2022-09-02 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| GB202012181D0 (en) * | 2020-08-05 | 2020-09-16 | Autolus Ltd | Chimeric receptor |
| WO2022036159A2 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| WO2022197933A1 (en) | 2021-03-18 | 2022-09-22 | The Broad Institute, Inc. | Compositions and methods for characterizing lymphoma and related conditions |
| WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
| CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN116836301A (zh) * | 2022-07-08 | 2023-10-03 | 上海君赛生物科技有限公司 | 基于TGF-beta抗体的陷阱受体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7173002B2 (en) * | 2001-04-24 | 2007-02-06 | Mcgill University | 150 KDA TGF-B1 accessory receptor acts a negative modulator of TGF-B signaling |
| JP4742025B2 (ja) * | 2003-01-31 | 2011-08-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変異ニューブラスチンのポリマー結合体 |
| ES2359004T3 (es) * | 2004-08-06 | 2011-05-17 | Onyx Therapeutics, Inc. | Compuestos para inhibición enzimática de proteasoma. |
| ATE439383T1 (de) * | 2005-09-20 | 2009-08-15 | Peter Jon Nelson | Gewebeinhibitor für metalloproteinasen (timp) gebunden an ein glycosylphosphatidylinositol (gpi-) anker zur behandlung von krebs |
| DE102006051796A1 (de) * | 2006-11-03 | 2008-05-08 | Merck Patent Gmbh | Triaza-benzo[e]azulenderivate |
| CN102850458B (zh) * | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2015027082A1 (en) * | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
-
2018
- 2018-01-19 US US16/480,391 patent/US20190352373A1/en not_active Abandoned
- 2018-01-19 WO PCT/EP2018/051287 patent/WO2018138003A1/en unknown
- 2018-01-19 CN CN201880008625.9A patent/CN110709416A/zh active Pending
- 2018-01-19 KR KR1020197023524A patent/KR20190111058A/ko unknown
- 2018-01-19 EP EP18705087.7A patent/EP3574006A1/en not_active Withdrawn
- 2018-01-19 AU AU2018212403A patent/AU2018212403A1/en not_active Abandoned
- 2018-01-19 SG SG11201906552WA patent/SG11201906552WA/en unknown
- 2018-01-19 JP JP2019560469A patent/JP2020505069A/ja active Pending
- 2018-01-24 TW TW107102534A patent/TW201831193A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190352373A1 (en) | 2019-11-21 |
| WO2018138003A1 (en) | 2018-08-02 |
| JP2020505069A (ja) | 2020-02-20 |
| KR20190111058A (ko) | 2019-10-01 |
| CN110709416A (zh) | 2020-01-17 |
| EP3574006A1 (en) | 2019-12-04 |
| TW201831193A (zh) | 2018-09-01 |
| AU2018212403A1 (en) | 2019-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
| SG11201900634VA (en) | Chimeric antigen receptor | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201903304YA (en) | IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS | |
| SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201807785VA (en) | Neuroactive steroids, compositions, and uses thereof | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201900147WA (en) | Digital property management on a distributed transaction consensus network | |
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201807325UA (en) | Optimizing range of aircraft docking system | |
| SG11201906963QA (en) | Binding agents | |
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof |